Richard A. Basile
– Co-Founder and CEO
Mr. Basile is a biopharmaceutical executive with 35 years of international biopharmaceutical industry experience with early-stage and Fortune 100 Pharma/Biotech companies, including licensing, mergers and acquisitions, product development, sales, marketing and launch in anti-infective, cardiovascular, immunological, dermatologic, CNS and metabolic disease segments, including biotechnology and protein therapeutic products such as Factor VIII for treatment of a rare clotting disorder, Hemophilia. Mr. Basile served as the global Vice President of corporate strategy, finance, and business development of a $1.2 billion international biologics business unit at Bayer AG (Bayer Biologicals). Mr. Basile also served in several senior marketing, sales and strategic marketing capacities’ at Bayer Pharmaceuticals, and was President and General Manager of a Bayer subsidiary, Rhein Chemie Corporation. More recently, Mr. Basile was the founding CEO of Entegrion (formerly Hemocellular Therapeutics), an early stage biotech company founded on UNC-CH invention in homeostasis, Executive VP at MylanBertek, and was the global commercial head of Diosynth Biotechnology, part of Organon Biosciences where he also served on the executive management team of Organon (now Merck & Co) responsible for biotechnology business development, with focus on oncology and immunology. As a founder of BioPontis Alliance, Mr. Basile has frequently advocated for a new paradigm in advancing academic research into cures, and has presented to the National Academy’s (Government University Industry Research Roundtable) among other government, academic and industry conferences.
PhD – CSO
Dr. Spencer is Chief Scientific Officer of BioPontis Alliance for Rare Disease, where he is responsible for drug discovery and development programs in neurological rare diseases. He has 30 years of experience in both large pharmaceutical and small biotech environments, where he has directly managed discovery, non-clinical (CMC) development, clinical development, regulatory, manufacturing, QA/QC and marketing disciplines. Prior to his current role, he was Chief Operating Officer and Chief Scientific Officer of Proteovec LLC, a company specializing in novel protein expression and purification technologies. From 2001 to 2012, he was Chief Operating Officer and SVP of R&D of Biolex Therapeutics, a venture-funded biotechnology company. Prior to Biolex, David was VP of Plasma Products Lifecycle Management and led global clinical development for Bayer’s Biological Products division in immunology, neurology, hematology, respiratory and critical care therapeutic areas. Earlier, he held leadership roles in central nervous system drug discovery, project management and commercial evaluation of cardiovascular pipeline products at Bayer AG in Germany. In addition to his duties at BioPontis, he also leads Biotechnology Enterprise Management, a biotechnology consultancy.